Protara Therapeutics (TARA) said late Thursday it launched a public offering of $75 million of common shares and pre-funded warrants.

The company plans to grant underwriters a 30-day overallotment option to purchase additional shares, according to a statement.

Net proceeds will be used to advance clinical programs, including the development of the TARA-002 immunotherapy for certain types of cancers, as well as for general corporate purposes, the company said.